BioCentury
ARTICLE | Company News

NICE backs narrowed Efient use

September 5, 2009 12:52 AM UTC

The U.K.'s NICE issued a final appraisal determination (FAD) that supports use of cardiovascular drug Efient prasugrel from Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) and Eli Lilly and Co. (NYSE:LLY) in a patient population that is narrower than the drug's label. The agency recommended use of the thienopyridine P2Y12 receptor antagonist in combination with aspirin to prevent atherothrombotic events in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) -- its licensed indication -- only when immediate primary PCI for ST-segment-elevation myocardial infarction is necessary, when stent thrombosis has occurred during clopidogrel use or in patients with diabetes mellitus. ...